SOP for FDA Clinical Hold/Partial Hold Communications and Remediation

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-fda-clinical-hold-partial-hold-communications-and-remediation”
},
“headline”: “SOP for FDA Clinical Hold/Partial Hold Communications and Remediation”,
“description”: “This SOP defines procedures for managing FDA-imposed clinical hold or partial hold under 21 CFR 312.42. It covers sponsor and investigator responsibilities, communication with FDA and IRB, remediation actions, timelines, and resumption of trial activities.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Published on 26/12/2025

Standard Operating Procedure for FDA Clinical Hold/Partial Hold Communications and Remediation

SOP No.	CR/OPS/132/2025
Supersedes	NA
Page No.	1 of 73
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Table of Contents

Purpose

The purpose of this SOP is to outline procedures for managing communications and remediation when the U.S. Food and Drug

Administration (FDA) imposes a clinical hold or partial hold on an IND-regulated study under 21 CFR 312.42. It ensures timely resolution, protection of subject safety, and compliance with regulatory requirements.

Scope

This SOP applies to sponsors, investigators, CROs, regulatory affairs, and QA teams involved in clinical trials under IND oversight. It covers receipt of FDA hold notifications, communication with sites, subject safety measures, remediation planning, submissions to FDA, and trial resumption.

Responsibilities

Sponsor: Coordinates responses to FDA, prepares remediation plans, and oversees CAPA implementation.
Investigator: Ensures trial suspension at site level, safeguards subjects, and communicates with IRB.
CRO: Assists in tracking corrective actions and monitors site compliance during hold.
Regulatory Affairs: Manages FDA communications and formal submissions.
QA: Audits remediation and ensures inspection readiness.
IRB/EC: Reviews site-level implications and safety measures.

Accountability

The Sponsor’s Regulatory Head is accountable for ensuring compliance with FDA hold requirements. Investigators are accountable for site-level trial suspension and subject safety.

Procedure

1. Receipt of FDA Hold Notification
1.1 Document FDA hold letter upon receipt.
1.2 Record in Clinical Hold Log (Annexure-1).

2. Immediate Actions
2.1 Suspend subject enrollment immediately.
2.2 Notify investigators, CRO, and IRB.
2.3 Ensure subject safety monitoring continues.
2.4 Record in Site Notification Log (Annexure-2).

3. Root Cause Analysis and Remediation
3.1 Conduct investigation into issues cited by FDA.
3.2 Develop corrective and preventive action (CAPA) plan.
3.3 Document in Remediation Log (Annexure-3).

4. FDA Communication
4.1 Submit remediation plan to FDA within required timelines.
4.2 Maintain FDA Communication Log (Annexure-4).

5. Site and Subject Management
5.1 Inform subjects if their participation is affected.
5.2 Provide alternative medical care where needed.
5.3 Document in Subject Communication Log (Annexure-5).

6. Trial Resumption
6.1 Resume study activities only after FDA issues “Hold Lifted” notification.
6.2 Record in Trial Resumption Log (Annexure-6).

7. Archiving
7.1 Archive hold-related correspondence, CAPA documentation, and FDA responses in TMF and ISF.
7.2 Retain per regulatory timelines.

Abbreviations

SOP: Standard Operating Procedure
CAPA: Corrective and Preventive Action
FDA: Food and Drug Administration
IND: Investigational New Drug
IRB/EC: Institutional Review Board/Ethics Committee
CRO: Contract Research Organization
QA: Quality Assurance
TMF: Trial Master File
ISF: Investigator Site File

Documents

Clinical Hold Log (Annexure-1)
Site Notification Log (Annexure-2)
Remediation Log (Annexure-3)
FDA Communication Log (Annexure-4)
Subject Communication Log (Annexure-5)
Trial Resumption Log (Annexure-6)

References

Version: 1.0

Approval Section

Prepared By	Ravi Kumar, Regulatory Affairs Specialist
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Clinical Operations

Annexures

Annexure-1: Clinical Hold Log

Date	Protocol ID	FDA Notification	Recorded By	Status
01/09/2025	IND-2025-01	Full Hold	Reg Affairs	Open

Annexure-2: Site Notification Log

Date	Site	Notification Type	Sent By	Status
01/09/2025	NY Clinical Center	Enrollment Suspension	Sponsor	Completed

Annexure-3: Remediation Log

Date	Issue	CAPA Action	Responsible	Status
02/09/2025	Inadequate Safety Data	Submit Additional Reports	Safety Officer	Ongoing

Annexure-4: FDA Communication Log

Date	FDA Contact	Submission Type	Submitted By	Status
03/09/2025	Dr. John Smith	Remediation Plan	Reg Affairs	Filed

Annexure-5: Subject Communication Log

Date	Subject ID	Communication	Investigator	Status
04/09/2025	S101	Hold Notification	Investigator	Completed

Annexure-6: Trial Resumption Log

Date	Protocol ID	FDA Decision	Recorded By	Status
10/09/2025	IND-2025-01	Hold Lifted	Reg Affairs	Resumed

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head Clinical Operations

For more SOPs visit: Pharma SOP